10-Q: PetVivo Q2 2026: Revenue Up, Losses Widen Amid Strategic Shifts

PetVivo Holdings, Inc. reported increased revenue driven by new product sales but saw a wider net loss for Q2 2026, alongside significant debt conversions and ongoing going concern doubts.

Summary

• Revenue for the three months ended September 30, 2025, increased to $303,284 from $200,720 in the prior year period, primarily due to sales of PrecisePRP products.
• Net loss for the three months ended September 30, 2025, widened to $3,007,809 ($0.11 per share) from $2,175,493 ($0.11 per share) in the prior year.
• For the six months ended September 30, 2025, revenue increased to $600,784 from $324,470, driven by PrecisePRP sales.
• Net loss for the six months ended September 30, 2025, increased to $5,318,846 ($0.20 per share) from $4,222,556 ($0.22 per share) in the prior year.
• The increased net loss was primarily due to an unrealized loss on change in derivative liabilities, loss on disposal of assets, and amortization of debt discount.
• Cash balance as of September 30, 2025, was $767,914, up from $227,689 at March 31, 2025.
• Working capital as of September 30, 2025, was $1,057,029.
• The company converted $1,850,000 in convertible notes plus $168,154 in accrued interest into 3,669,806 shares of common stock on September 30, 2025.
• An exclusive licensing agreement was signed with VetStem, Inc. for PrecisePRP products, contributing to new revenue streams.
• An exclusive licensing agreement was signed with Digital Landia Holding Corp for AI software in the veterinary industry.
• The company terminated its distribution agreements with MWI and Covetrus and entered new partnerships with Vedco and Clipper.
• Substantial doubt exists about the company's ability to continue as a going concern, though recent capital raise is expected to fund operations until December 31, 2025.
• Material weaknesses in internal control over financial reporting were identified, with remediation efforts ongoing.

Sentiment

Score: 3

Explanation: While revenue growth from new products and strategic partnerships are positive, the widening net loss, substantial cash burn from operations, and explicit "going concern" warning indicate significant financial distress. The material weaknesses in internal controls add to the negative sentiment. The recent capital raise provides temporary relief but highlights ongoing funding needs.

Positives

• Total revenues increased by 51% for the three months ended September 30, 2025, to $303,284, and by 85% for the six months ended September 30, 2025, to $600,784, compared to the prior year periods.
• New product sales from PrecisePRP, under an exclusive licensing agreement with VetStem, Inc., contributed significantly to revenue growth, generating $116,382 in Q3 2025 and $265,639 in 6M 2025.
• Operating loss decreased for both the three months ($2,065,367 vs $2,173,040) and six months ($3,909,684 vs $4,217,473) ended September 30, 2025, due to cost-cutting initiatives in General and Administrative (G&A) and Research and Development (R&D) expenses.
• Cash balance increased to $767,914 as of September 30, 2025, from $227,689 at March 31, 2025, largely due to financing activities.
• Successful completion of a $5,000,000 Series B preferred stock private placement offering, with $4,400,000 fully funded by June 24, 2025.
• Secured an exclusive licensing agreement with Digital Landia Holding Corp for AI software, expanding technological capabilities.
• New distribution partnerships with Vedco, Inc. and Clipper Distributing, LLC are generating sales, with Vedco contributing $227,498 in Q3 2025 and $425,878 in 6M 2025.
• A second ISO cleanroom manufacturing facility is expected to be operational later this year, aiming to minimize supply risks and scale production.

Negatives

• Net loss widened for the three months ended September 30, 2025, to $3,007,809 from $2,175,493 in the prior year period.
• Net loss also widened for the six months ended September 30, 2025, to $5,318,846 from $4,222,556 in the prior year period.
• Other expense significantly increased to $942,442 for Q3 2025 and $1,409,162 for 6M 2025, primarily due to unrealized loss on derivative liabilities ($320,404 for 6M), loss on disposal of assets ($149,125 for 6M), and amortization of debt discount ($936,552 for 6M).
• Cost of sales increased substantially to $83,226 for Q3 2025 and $194,000 for 6M 2025, compared to $21,162 and $34,156 respectively in the prior year periods, due to new product sales.
• Research and Development expenses decreased due to "tight cash flow constraints," indicating financial pressure impacting strategic investments.
• The company incurred $314,768 in fees for early termination of a ten-year lease agreement for production and warehouse space.
• The company continues to incur substantial losses from operations and has an accumulated deficit of $96,670,939 as of September 30, 2025.
• Net cash used in operating activities was $3,828,209 for the six months ended September 30, 2025.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to continued losses from operations and a significant accumulated deficit of $96,670,939.
• Need to raise additional capital in the future to fund commercialization efforts for Spryng and PrecisePRP products and ongoing operations, with no guarantee of success.
• Material weaknesses in internal control over financial reporting related to the accounting for modifications of convertible notes, measurement of beneficial conversion features, warrant debt discounts, and derivative liabilities.
• Potential adverse effects on business, financial condition, results of operations, and stock price from a U.S. federal government shutdown or a sustained period of economic disruption, including reduced government spending, supply chain disruptions, limited access to capital markets, reduced consumer confidence, and impact on economic data.
• Reliance on estimates and assumptions in financial statements, such as allowance for credit losses, inventory obsolescence, useful lives of assets, and fair value of share-based payments, which could differ from actual results.
• Concentration risk as cash is maintained with various financial institutions, potentially exceeding federally insured limits at times.
• The company's ability to maintain exclusivity for the VetStem PrecisePRP license is contingent on mutually agreed upon annual minimum purchases during the first five years.

Future Outlook

The company anticipates growing its product pipeline through acquisition or in-licensing of additional proprietary products for pets and may establish strategic out-licensing partnerships for secondary revenues. A second ISO cleanroom facility is expected to be operational later this year to minimize supply risks and scale production. Management believes the proceeds from the Series B preferred stock offering are sufficient to fund operations until December 31, 2025, but acknowledges the need to raise additional capital in the future to support commercialization efforts and ongoing operations.

Management Comments

• "This is a game changer for veterinarians and their ability to treat their patients with PRP, said Mike Eldred, PetVivo Board Member. This innovative, and FDA reviewed product, will be a great addition to Spryng with OsteoCushion technology, and supports our strategy to be the leader in veterinary medical devices and regenerative medicine."
• "We believe that the increased revenues and margins provided by Spryng will accelerate its adoption rate and propel it forward as the standard of care for canine and equine lameness related to or due to synovial joint issues."
• "Management believes that the actions presently being taken to further implement its business plan will enable the Company to continue as a going concern."
• "We expect to continue to raise additional capital through the sale of our securities from time to time for the foreseeable future to fund our business expansion."

Industry Context

The company operates in the growing companion animal veterinary care and product sales market, estimated at $11 billion. It aims to provide alternatives to traditional osteoarthritis treatments, such as NSAIDs, which have potential side effects. The introduction of PrecisePRP, an off-the-shelf platelet-rich plasma product, positions the company in the regenerative medicine segment, offering a unique, consistent, and convenient solution compared to existing PRP mechanical kits. The company's strategy to leverage human biomedical applications for veterinary use and expand through licensing agreements aligns with trends seeking innovative, biocompatible solutions in animal health.

Comparison to Industry Standards

• Spryng offers an alternative to traditional osteoarthritis treatments like NSAIDs, which can have gastrointestinal, kidney, and liver damage side effects, by addressing the affliction rather than just symptoms.
• Spryng's single injection cost of approximately $600 to $900 per joint, lasting at least 12 months, is presented as an effective and economical solution compared to other treatments.
• PrecisePRP is highlighted as a "first-in-class off-the-shelf platelet-rich plasma (PRP) product" that does not require a blood draw or centrifugation, unlike "any PRP mechanical kits currently on the market," offering uniformity and consistency (4 billion platelets per vial at 500,000 platelets per microliter).
• PrecisePRP's safety studies in dogs and horses, conducted at the request of the FDA, reported no treatment-related adverse events, suggesting a strong safety profile compared to potential risks with other treatments.

Corporate Governance

Stakeholder Impact

• Shareholders: Significant dilution from conversion of debt to common stock (3,669,806 shares issued), and ongoing need for future capital raises could lead to further dilution. The "going concern" warning poses a substantial risk to investment value.
• Employees: Stock-based compensation is a significant part of remuneration. The company made contributions to its 401(k) plan.
• Customers (Veterinarians): New product offerings (PrecisePRP) and distribution partnerships aim to expand product availability and provide new treatment options for animal health.
• Creditors: Convertible notes were largely converted to equity, reducing debt, but the going concern warning indicates ongoing financial risk.
• Suppliers: Increased inventory levels and supplier advances suggest continued operational activity, but cash flow constraints could impact payment terms.

Next Steps

• Increase commercialization efforts for Spryng in the United States through distribution relationships, sales reps, clinical studies, and market awareness.
• Initiate additional clinical studies to expand distribution outlets, as large distributors generally require third-party university studies.
• Bring a second ISO cleanroom manufacturing facility online later this year to minimize supply risks and scale production capacity.
• Grow the product pipeline through the acquisition or in-licensing of additional proprietary products from human medical device companies for use in pets.
• Potentially establish strategic out-licensing partnerships to provide secondary revenues.
• Continue remediation efforts for material weaknesses in internal control over financial reporting, with completion expected by March 31, 2026.
• Raise additional capital in the future to support commercialization efforts and ongoing operations beyond December 31, 2025.

Key Dates

Recommendation

Despite revenue growth from new product introductions and strategic partnerships, the company faces severe financial challenges, including a widening net loss, substantial cash burn from operations, and an explicit 'going concern' warning. The identified material weaknesses in internal controls further erode confidence. While a recent capital raise provides temporary liquidity, the ongoing need for additional funding and the significant dilution from recent debt conversions present considerable risks. The overall financial health and operational stability are highly concerning, suggesting a 'sell' recommendation for investors to mitigate potential further losses.

Keywords

PetVivo Holdings, PETV, 10-Q, Quarterly Report, Animal Health, Veterinary Medical Devices, Spryng, OsteoCushion Technology, PrecisePRP, Platelet-Rich Plasma, VetStem, Digital Landia Holding Corp, AI Software, Biomaterials, Osteoarthritis, Canine Health, Equine Health, SEC Filing, Financial Results, Going Concern, Capital Raise, Distribution Agreements, Internal Controls, Biomedical Device